Retatrutide is an investigational triple-hormone-receptor agonist being studied for weight management and metabolic disease. It is not FDA-approved for any use. This page is educational and not medical advice.

Last updated: July 2, 2026

What Is Retatrutide?

Retatrutide is an investigational drug designed to activate three receptors — GIP, GLP-1, and glucagon. It has not been approved by the FDA for any indication and remains in clinical development. It is not a branded product and is not an approved medication; any discussion of it occurs only with a licensed provider, where clinically appropriate and legally available.

How It Works

Retatrutide is being studied for combined activity at the GIP, GLP-1, and glucagon receptors. GIP and GLP-1 pathways are involved in appetite and insulin signaling; glucagon-receptor activity is being investigated for possible effects on energy expenditure and metabolism. Because retatrutide remains investigational, this is not an established treatment mechanism, and its effects in general patient use are not established.

What It’s Studied For

Retatrutide is being evaluated in ongoing clinical trials for obesity and related metabolic conditions. Its safety, effectiveness, approval status, labeling, and eventual therapeutic role all remain under investigation, and human data are early. This page does not present outcome figures because retatrutide is not approved and its efficacy is not established for general use.

What to Expect

Because retatrutide is investigational, no approved use, dosing, timeline, or expected outcome can be represented. Long-term and real-world safety are not established. Treatment is not guaranteed and is not equivalent to any FDA-approved medication.

Preferred Starting Options / Dosing Notes

Many patients begin with a lower starting option so a licensed clinician can evaluate tolerance, medical history, goals, and safety factors before any adjustments are considered. The starting option shown below is informational and reflects available program data, not self-directed dosing instructions. Final medication, dose, frequency, and treatment plan are determined by a licensed clinician.

Safety Considerations

• The safety profile is still being defined.
• Trial-reported effects have generally been consistent with incretin-based therapies, including gastrointestinal effects, but long-term and real-world safety are unknown.
• The FDA has warned about unapproved GLP-1-class products sold directly to consumers, including those falsely labeled as 'research' products.
• Because retatrutide is investigational, its risks are not fully characterized.

Who Is Not a Candidate

Given its investigational status, retatrutide is not an established treatment for any population. A licensed clinician reviews weight history, metabolic and cardiovascular status, gastrointestinal/pancreatitis/gallbladder history, pregnancy status, current medications, and legal availability, and may determine it is not appropriate.

How It Compares

Semaglutide acts on one receptor (GLP-1); tirzepatide on two (GIP and GLP-1); retatrutide is being studied as a three-receptor agonist (GIP, GLP-1, glucagon). Unlike the other two, retatrutide is not FDA-approved in any form. No comparative effectiveness is claimed.

Frequently Asked Questions

References

• ClinicalTrials.gov — retatrutide (TRIUMPH program)
• Peer-reviewed retatrutide Phase 2 trial publications
• FDA statements on unapproved GLP-1-class products